Endothelin receptor antagonists: another potential alternative for cardiovascular diseases

Area of Science:

• Cardiovascular Pharmacology
• Renal Physiology
• Endocrinology

Background:

• Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in cardiovascular diseases.
• ET-1 exerts its effects via ETA and ETB receptors, overexpressed in hypertension and renal failure.
• ET-1 receptor antagonists are a novel therapeutic approach for cardiovascular conditions.

Purpose of the Study:

• To review the therapeutic potential of ET-1 receptor antagonists in cardiovascular diseases.
• To compare the efficacy of selective ETA versus combined ETA/ETB antagonists in experimental models.
• To investigate the role of ET-1 in hypertension-induced end-organ damage.

Main Methods:

• Review of experimental models of cardiovascular diseases and hypertension.
• Analysis of studies comparing selective ETA and dual ETA/ETB antagonists.
• Evaluation of the impact of ET-1 receptor blockade on vascular and renal parameters.

Main Results:

• Endothelin antagonists improve vascular function and reduce hypertrophy and glomerulosclerosis, independent of blood pressure reduction.
• Selective ETA and dual ETA/ETB antagonists show similar effects on hemodynamics and remodeling in experimental models.
• In salt-sensitive hypertension, ETA blockade prevents vascular hypertrophy and improves renal function, with evidence suggesting ETB receptor involvement.

Conclusions:

• ET-1 receptor antagonists may be valuable in preventing hypertension-induced end-organ damage.
• The comparative efficacy of selective ETA versus dual ETA/ETB blockade for preventing human target organ injuries requires further investigation.
• Understanding the specific roles of ETA and ETB receptors is crucial for optimizing therapeutic strategies.